US20080057123A1 - Controlled Release Formulations - Google Patents

Controlled Release Formulations Download PDF

Info

Publication number
US20080057123A1
US20080057123A1 US11/847,012 US84701207A US2008057123A1 US 20080057123 A1 US20080057123 A1 US 20080057123A1 US 84701207 A US84701207 A US 84701207A US 2008057123 A1 US2008057123 A1 US 2008057123A1
Authority
US
United States
Prior art keywords
formulation
weight
agents
release
core
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/847,012
Other languages
English (en)
Inventor
Pascal Grenier
Alain Nhamias
Guy Vergnault
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jagotec AG
Original Assignee
Jagotec AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38686769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20080057123(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jagotec AG filed Critical Jagotec AG
Priority to US11/847,012 priority Critical patent/US20080057123A1/en
Assigned to JAGOTEC AG reassignment JAGOTEC AG ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: GRENIER, PASCAL, VERGNAULT, GUY, NHAMIAS, ALAIN
Publication of US20080057123A1 publication Critical patent/US20080057123A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • This invention is generally in the field of controlled or modified release formulations of pharmaceutically active agents.
  • a controlled release formulation is a pharmaceutical composition capable of releasing a drug at a pre-determined rate and/or at a pre-determined time after administration to maintain a desirable pharmacological activity for some desirable period of time.
  • Such preparations provide a supply of a drug to the body during a predetermined period of time or at a predetermined absorption site and thus maintain drug levels in a therapeutic range for longer periods of time than conventional, e.g. immediate release formulations.
  • Dosage forms comprising a core containing a drug dispersed in release-controlling materials are a popular means of producing controlled release formulations.
  • Materials most commonly employed for this purpose are hydrophilic materials, e.g. hydrophilic polymers that swell and gel upon contact with a physiological medium.
  • hydrophilic materials e.g. hydrophilic polymers that swell and gel upon contact with a physiological medium.
  • the periphery When a dosage form is exposed to a physiological medium, the periphery will begin to hydrate and form a gel matrix. As the medium continues to penetrate the dosage form the thickness of the gel matrix increases. Drug release occurs by diffusion through the matrix and/or by erosion of the matrix.
  • a variety of desirable release profiles can be produced by carefully selecting the hydrophilic material and the dimensions and geometry of the dosage form compositions. However, over time, as the thickness of the gel matrix increases, the drug concentration in the dosage form decreases, the surface area of the dosage form decreases and as a result the rate of release decreases.
  • an absorption window is a term given to an area or region of the GI tract where a drug is absorbed more efficiently or at a higher rate compared with other regions of the GI tract. Some active agents are more prone to degradation or metabolism in certain regions of the GI tract than others. As such, it would be beneficial if a controlled release dosage form could deliver the drug almost exclusively to a particular absorption window for a given active agent, or preferentially avoid or reduce the rate of release in areas of the GI tract where degradation or metabolism of an active agent is high. Further, the ability to deliver an active agent to the absorption window may increase efficacy of the drug substances and/or diminish or eliminate adverse side effects.
  • the formulation contains a core containing an active agent and an enteric material, optionally a hydrophilic material and, optionally one or more barrier layers.
  • the formulation can be administered in any solid oral dosage form such as a tablet or caplet.
  • the controlled release formulation is a tablet containing a core containing a dihydropyridine calcium channel blocker, such as nisoldipine, and an enteric material, and at least one barrier layer above or below the central layer which contains one or more erodible, swellable and/or gellable polymeric materials.
  • the concentration of the enteric material in the core is from about 0.1% to about 20% by weight, preferably about 1 to 15%, more preferably about 5 to 10% by weight of the composition.
  • the concentration of the one or more polymers in the barrier layer(s) is from about 5% to about 90% by weight of the barrier layer, preferably from about 50% to about 90% by weight of the barrier.
  • the tablet is a trilayer tablet which contains a core, and two barrier layers, one above the core and one below.
  • the barrier layers may be the same or different in composition and thickness.
  • the core and/or barrier layers may contain one or more pharmaceutically acceptable additives, excipients, or carriers.
  • the core may contain one or more polymeric materials that modulate (i.e. slow and/or accelerate) the release of the active agent.
  • concentration of the polymeric material is from about 1% to about 95% by weight.
  • the central layer and/or the barrier layers may also contain one or adjuvants, which, in combination with the polymeric materials, further modulate release of the active agent.
  • concentration of the adjuvant(s) is from about 1% to about 25% by weight of the compositions, preferably from about 5% to about 15% by weight of the composition.
  • the formulation may be coated with one or more modified release coatings, which further modulate the release of the active agent from the core. Suitable coatings include immediate release coatings, taste mask coatings, enteric coatings, sustained or extended release coatings, and delayed release coatings.
  • the dosage forms may also be coated for aesthetic reasons such as to impart a color to the dosage form or to apply a surface finish to the dosage form.
  • the dosage form upon administration to a subject, releases the active agent with an ascending release rate in response to the changes in pH as the dosage formulation descends the GI tract.
  • enteric material refers to a material that is typically employed in enteric coatings. Enteric materials are practically insoluble at acidic pH levels found in the stomach, but are increasingly soluble at higher pH levels found in the intestinal tract.
  • Taste masking coating refers to a pH dependent coating that is insoluble in the mouth but dissolves in the acidic pH of the stomach.
  • Extended release coating refers to a pH independent substance that will act as a barrier to control the diffusion of the drug from its core complex into the gastrointestinal fluids.
  • Delayed release coating refers to a pH dependent coating that is insoluble in the acidic pH of the stomach and the pH within the mid to the upper small intestine, but dissolves within the lower small intestine or upper large intestine.
  • C max refers to the peak concentration in blood plasma. Unless otherwise stated, C max refers to the peak concentration of the calcium channel blocker in blood plasma.
  • T max refers to the time to peak concentration in blood plasma. Unless otherwise stated, T max refers to the time to peak concentration of the calcium channel blocker in blood plasma.
  • ⁇ z refers to the elimination rate constant.
  • T 1/2 refers to the terminal half-life.
  • AUC last refers to the area under the concentration-time curve from time-zero to the time of the last quantifiable concentration.
  • AUC inf refers to the area under the plasma concentration time curve from time-zero extrapolated to infinity.
  • Bioavailability refers to the rate and of uptake the active ingredient or active agent absorbed from a drug product.
  • Bioequivalence refers to the equivalent release of the same drug substance from two or more drug products or formulations. This leads to an equivalent rate and extent of absorption from these formulations.
  • an “analog” of a chemical compound is a compound that, by way of example, resembles another in structure but is not necessarily an isomer (e.g., 5-fluorouracil is an analog of thymine).
  • a “derivative” of a compound refers to a chemical compound that may be produced from another compound of similar structure in one or more steps. Derivatives generally involve the addition and/or modification of one or more functional groups on the parent compound.
  • controlled release elements refers to materials that modulate release of the active agent from the formulation.
  • the controlled release elements may be located in the core and/or the barrier layer(s).
  • the controlled release elements may be organic or inorganic, naturally occurring or synthetic, materials including, but not limited to, polymeric materials, triglycerides, derivatives of triglycerides, fatty acids and salts of fatty acids, talc, small organic molecules and salts thereof, talc, boric acid, and colloidal silica.
  • coat-core nisoldipine 40 mg tablet for purposes of comparison of pharmacokinetics and dosage refers to the version of the drug marketed as SULAR®, containing 8 mg of nisoldipine in the core and 32 mg of nisoldipine in the coat.
  • the core or central layer contains one or more active agents selected from the group including, but not limited to, hypnotics, sedatives, tranquilizers, anti-convulsants, muscle relaxants, analgesics, anti-inflammatory, anesthetics, anti-spasmodics, anti-ulcer-agents, anti-parasitics, anti-microbials, anti-fungal, cardiovascular agents, diuretics, cytostatics, anti-neoplastic agents, anti-viral agents, anti-glaucoma agents, anti-depressants, sympathomimetics, hypoglycaemics, diagnostic agents, anti-cough, physic energizers, anti-parkinson agents, local anesthetics, muscle contractants, anti-malarials, hormonal agents, contraceptives, anorexic, anti-arthritic, anti-diabetic, anti-hypertensive, anti-pyretic, anti-cholinergic, bronchodilator, central nervous system, inotropic
  • Suitable active agents include, but are not limited to, codeine, ethylmorphine, dextromethorphan, noscapine, pentoxiverine, acetylcysteine, bromhexine, epinephrine, isoprenaline, orciprenaline, ephedrine, fenoterol, rimiterol, ipratropium, cholinetheophyllinate, proxiphylline, bechlomethasone, budesonide, deslanoside, digoxine, digitoxin, disopyramide, proscillaridin, chinidine, procainamide, mexiletin, flecainide, alprenolol, proproanolol, nadolol, pindolol, oxprenolol, labetalol, timolol, atenolol, pentaeritrityltetranitrate, is
  • the active agent(s) can be chiral or achiral. Chiral molecules can exist as a single enantiomer, a mixture of enantiomers or diastereomers or a racemic mixture.
  • stereoisomers refers to compounds made up of the same atoms having the same bond order but having different three-dimensional arrangements of atoms which are not interchangeable. The three-dimensional structures are called configurations.
  • enantiomers refers to two stereoisomers which are non-superimposable mirror images of one another.
  • optical isomer is equivalent to the term “enantiomer”.
  • the term “diastereomer” refers to two stereoisomers which are not mirror images and are not superimposable.
  • the terms “racemate”, “racemic mixture” or “racemic modification” refer to a mixture of equal parts of enantiomers.
  • the term “chiral center” refers to a carbon atom to which four different groups are attached. Choice of the appropriate chiral column, eluent, and conditions necessary to effect separation of the pair of enantiomers is well known to one of ordinary skill in the art using standard techniques (see e.g. Jacques, J. et al., “Enantiomers, Racemates, and Resolutions”, John Wiley and Sons, Inc. 1981).
  • pharmaceutically acceptable salts refer to derivatives of the compounds listed above, wherein the parent compound is modified by making the acid or base addition salt thereof.
  • Example of pharmaceutically acceptable salts include but are not limited to mineral or organic acid salts of basic residues such as amines; and alkali or organic salts of acidic residues such as carboxylic acids.
  • the pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids.
  • Such conventional non-toxic salts include those derived from inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids; and the salts prepared from organic acids such as acetic, propionic, succinic, glycolic, stearic, lactic, malic, tartaric, citric, ascorbic, pamoic, maleic, hydroxymaleic, phenylacetic, glutamic, benzoic, salicylic, sulfanilic, 2-acetoxybenzoic, fumaric, tolunesulfonic, naphthalenesulfonic, methanesulfonic, ethane disulfonic, oxalic, and isethionic salts.
  • inorganic acids such as hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric, and nitric acids
  • organic acids such as acetic, propionic, succinic, glycolic, ste
  • the pharmaceutically acceptable salts of the compounds can be synthesized from the parent compound, which contains a basic or acidic moiety, by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, non-aqueous media like diethyl ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 20th ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000, p. 704; and “Handbook of Pharmaceutical Salts: Properties, Selection, and Use,” P. Heinrich Stahl and Camille G. Wermuth, Eds., Wiley-VCH, Weinheim, 2002.
  • pharmaceutically acceptable refers to those compounds, materials, compositions, and/or dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, or other problems or complications commensurate with a reasonable benefit/risk ratio.
  • the amount of active agent(s) employed in a dosage form will depend on the active agent(s) to be employed and the nature and severity of the condition to be treated.
  • the concentration of the active agent is generally from about 0.1% to about 90% by weight of the tablet, preferably from about 0.5% to about 20% by weight of the tablet, more preferably from about 1% to about 10% by weight of the tablet.
  • the concentration of the active agent is generally from about 0.1% to about 90% by weight of the core, preferably from about 0.5% to about 20% of the core, more preferably from about 1% to about 10% of the core.
  • the active agent is a dihydropyridine calcium channel blocker, such as nisoldipine or a derivative, analogue, or polymorph thereof.
  • Nisoldipine is a yellow crystalline substance, which is practically insoluble in water, but soluble in ethanol. Derivatives of nisoldipine, such as m-nisoldipine, are described in Wang et al., J. Chrom. B, 835, 71-76 (2006)).
  • the core or central layer contains an enteric material to delay the release of the one or more active agents until the formulation reaches the absorption window.
  • Suitable enteric materials include, but are not limited to, cellulose polymers, such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and methacrylic resins that are commercially available under the trade name Eudragit® (Rolu Pharma), such as poly(ethylacrylate-methylmethaerylate-triethylammonioethyl-metharylate chloride) (Eudragit® RS and Eudragit® RL) and poly(ethylacrylate-methylmethacrylate) (Eudragit® NE); alginates, alkali-soluble acrylic resins, hydroxypropyl methylcellulose phthalate, methacrylate-meth
  • the core may also contain one or more hydrophilic materials that modulate (i.e. slow and/or accelerate) the release of the active agent(s).
  • the hydrophilic material may be any of the materials known in the art used in dosage forms as matrix-forming release-controlling agents.
  • Such materials include, but are not limited to, methyl cellulose, carboxymethyl-cellulose sodium, crosslinked carboxymethylcellulose sodium, crosslinked hydroxypropylcellulose, hydroxypropylmethylcellulose, carboxymethyl starch, polymethacrylate, polyvinylpyrrolidone, polyvinyl alcohols, polyethylene glycols, potassium methacrylate-divinyl benzene copolymer, carboxymethylcellulose, alginates, albumin, gelatine, crosslinked polyvinylpyrrolidone, soluble starch and derivatives thereof, polyesters, polyanhydrides, polymethylvinylether/anhydride copolymers, glucan, scleroglucan, mannan, betacyclodextrins and cyclodextrin derivatives containing linear and/or branched polymeric chains and mixtures thereof.
  • the various types of the materials mentioned above are commercially and cab be characterized by differences in chemico-physical characteristics such as solubility and gel formation.
  • the erodibility, gelation, and ability to swell of hydroxypropylmethyl cellulose can vary based on the molecular weight of the polymer and the degree of substitution. Therefore, one skilled in the art would be able to select from among polymers with the same molecular structure but differing in the molecular weight and/or viscosity, based on the desired release profile of the active agent.
  • the core contains Methocel® K4M, a hydroxypropyl metlhycellulose having a methoxy content of 19-24%, a hydroxypropoxyl content of 7-12%, and an apparent viscosity, as measured on a 2% aqueous solution by rotation, of 2308-3755 mPa (Colorcon, West Point, Pa.).
  • the core contains Methocel® K100LV, a hydroxypropyl methycellulose having a methoxy content of 19-24%, a hydroxypropoxyl content of 7-12%, and an apparent viscosity, as measured on 2% aqueous solution by rotation, of 78-117 mPa (Colorcon, West Point, Pa.).
  • the concentration of the hydrophilic material is from about 1% to about 90% by weight of the composition, preferably from about 10% to about 50% by weight, more preferably from about 10 to 45% by weight of the composition.
  • the core containing the active agent, the enteric material and the hydrophilic material form a gel matrix.
  • the gel matrix must have sufficient strength such that it maintains its structural integrity throughout the period of drug release.
  • the enteric material remains insoluble.
  • the enteric material is increasingly solubilised, thereby increasingly creating pores and channels in the matrix through which drug can diffuse at increasing rates.
  • the enteric materials are not swellable and/or gellable in aqueous media, and thus, do not contribute mechanical strength of the gel matrix. It is important that the desirable effect the enteric material has on the release rate is not offset by the unintended effect of prematurely destroying the structural integrity of the gel matrix.
  • the enteric material is used in low amounts relative to the amount of hydrophilic material employed. Most preferably the ratio of hydrophilic material to the enteric material is about 1.5:1 to about 10:1, more particularly about 1.9:1 to about 5:1.
  • the barrier layer(s) serve to prevent, for a predetermined amount of time, the release of the active agent contained in the central layer or core.
  • the tablet can contain one or more barrier layers. When two barrier layers are present, the barriers layers may have the same composition or different compositions and/or the same thickness or different thicknesses.
  • the barrier layer(s) contain(s) one or more swellable, erodible and/or gellable polymers.
  • the swellable, erodible, and/or gellable polymer is hydroxypropylmethylcellulose.
  • the weight average molecular weight of the hydroxypropylmethylcellulose is from about 1000 to about 4,000,000, more preferably from about 2000 to about 2,000,000.
  • the barrier layer(s) contain Methocel® E5, a hydroxypropyl methycellulose having a methoxy content of 28-30%, a hydroxypropoxyl content of 7-12%, and an apparent viscosity, as measured by rotation, of 4.2-6.1 mPa (Colorcon, West Point, Pa.).
  • the barrier layer(s) contain Methocel® E50, a hydroxypropyl methycellulose having a methoxy content of 28-30%, a hydroxypropoxyl content of 7-12%, and an apparent viscosity, as measured by rotation, of 39-59 mPa (Colorcon, West Point, Pa.).
  • one barrier layer contains Methocel® ES and the second barrier layer contains Methocel® E50.
  • suitable polymers include, but are not limited to, carboxyvinyl polymers; polyvinylalcohols; glucans, scleroglucans; mannans; xantans; alginic acid and its derivatives; polyanhydrides; polyaminoacids; methylvinylethers/maleic anhydride copolymers; carboxymethylcellulose and its derivatives; ethylcellulose; methylcellulose; and other cellulosic polymers.
  • the polymers are present in an amount from about 5% to about 90% by weight of the barrier layer, preferably from about 25% to about 75% by weight of the barrier layer.
  • the core layer and/or the barrier layers may also contain one or more adjuvants, which in combination with the polymeric materials allows for further modulation of the release of the active agent based on the desired release profile of the active agent.
  • Suitable adjuvants include, but are not limited to, glyceryl monostearate, triglyceride derivatives, semi-synthetic glycerides, hydrogenated castor oil, glyceryl palmitostearate, cetyl alcohol, polyvinylpyrrolidone, glycerol, ethylcellulose, methylcellulose, sodium carboxymethylcellulose, other natural or synthetic substances well known to those skilled in the art, and combinations thereof.
  • Suitable adjuvants include, but are not limited to, magnesium stearate, stearic acid, talc, sodium benzoate, boric acid, polyoxyethylenglycols and colloidal silica.
  • concentration of the adjuvant(s) is from about 1% to about 25% by weight of the compositions, preferably from about 5% to about 15% by weight of the composition.
  • Formulations may be prepared using a pharmaceutically acceptable carrier composed of materials that are considered safe and effective and may be administered to an individual without causing undesirable biological side effects or unwanted interactions.
  • the carrier is all components present in the pharmaceutical formulation other than the active agent(s).
  • carrier includes, but is not limited to, plasticizers, diluents, binders, lubricants, surfactants, pH modifying agents, anti-adherents, disintegrators, fillers, pigments, colorants, stabilizing agents, flavoring agents, glidants, and combinations thereof.
  • Suitable plasticizers include, but are not limited to, hydrogenated castor oil, cetyl alcohol, cetostearyl alcohol, fatty acids, glycerides and triglycerides and derivatives thereof, and polyoxyethylenglycols and derivatives thereof.
  • Diluents also referred to as “fillers,” are typically necessary to increase the bulk of a solid dosage form so that a practical size is provided for compression of tablets or formation of beads and granules.
  • Suitable diluents include, but are not limited to, dicalcium phosphate dihydrate, calcium sulfate, lactose, sucrose, mannitol, sorbitol, cellulose, microcrystalline cellulose, kaolin, sodium chloride, dry starch, hydrolyzed starches, pregelatinized starch, silicone dioxide, titanium oxide, magnesium aluminum silicate and powdered sugar.
  • the amount of active substance released in the first administration phase may be programmed regulating the exposed surface and the components constituting the layer (a) matrix, all obviously depending on to the same active principle solubility.
  • Binders are used to impart cohesive qualities to a solid dosage formulation, and thus ensure that a tablet or bead or granule remains intact after the formation of the dosage forms.
  • Suitable binder materials include, but are not limited to, starch, pregelatinized starch, gelatin, sugars (including sucrose, glucose, dextrose, lactose and sorbitol), polyethylene glycol, waxes, natural and synthetic gums such as acacia, tragacanth, sodium alginate, cellulose, including hydroxypropylmethylcellulose, hydroxypropylcellulose, ethylcellulose, and veegum, and synthetic polymers such as acrylic acid and methacrylic acid copolymers, methacrylic acid copolymers, methyl methacrylate copolymers, aminoalkyl methacrylate copolymers, polyacrylic acid/polymethacrylic acid and polyvinylpyrrolidone.
  • Lubricants are used to facilitate tablet manufacture.
  • suitable lubricants include, but are not limited to, magnesium stearate, calcium stearate, stearic acid, glycerol behenate, polyethylene glycol, talc, and mineral oil.
  • Disintegrants are used to facilitate dosage form disintegration or “breakup” after administration, and generally include, but are not limited to, starch, sodium starch glycolate, sodium carboxymethyl starch, sodium carboxymethylcellulose, hydroxypropyl cellulose, pregelatinized starch, clays, cellulose, alginine, gums or cross linked polymers, such as cross-linked PVP (Polyplasdone XL from GAF Chemical Corp).
  • starch sodium starch glycolate, sodium carboxymethyl starch, sodium carboxymethylcellulose, hydroxypropyl cellulose, pregelatinized starch, clays, cellulose, alginine, gums or cross linked polymers, such as cross-linked PVP (Polyplasdone XL from GAF Chemical Corp).
  • Stabilizers are used to inhibit or retard drug decomposition reactions which include, by way of example, oxidative reactions.
  • Surfactants may be anionic, cationic, amphoteric or nonionic surface active agents.
  • Suitable anionic surfactants include, but are not limited to, those containing carboxylate, sulfonate and sulfate ions.
  • anionic surfactants include sodium, potassium, ammonium of long chain alkyl sulfonates and alkyl aryl sulfonates such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium dodecylbenzene sulfonate; dialkyl sodium sulfosuccinates, such as sodium bis-(2-ethylthioxyl)-sulfosuccinate; and alkyl sulfates such as sodium lauryl sulfate.
  • Cationic surfactants include, but are not limited to, quaternary ammonium compounds such as benzalkonium chloride, benzethonium chloride, cetrimonium bromide, stearyl dimethylbenzyl ammonium chloride, polyoxyethylene and coconut amine.
  • nonionic surfactants include ethylene glycol monostearate, propylene glycol myristate, glyceryl monostearate, glyceryl stearate, polyglyceryl-4-oleate, sorbitan acylate, sucrose acylate, PEG-150 laurate, PEG-400 monolaurate, polyoxyethylene monolaurate, polysorbates, polyoxyethylene octylphenylether, PEG-1000 cetyl ether, polyoxyethylene tridecyl ether, polypropylene glycol butyl ether, Poloxamer® 401, stearoyl monoisopropanolamide, and polyoxyethylene hydrogenated tallow amide.
  • amphoteric surfactants include sodium N-dodecyl-.beta.-alanine, sodium N-lauryl-.beta.-iminodipropionate, myristoamphoacetate, lauryl betaine and lauryl sulfobetaine.
  • the tablets may also contain minor amounts of nontoxic auxiliary substances such as wetting or emulsifying agents, dyes, pH buffering agents, or preservatives.
  • nontoxic auxiliary substances such as wetting or emulsifying agents, dyes, pH buffering agents, or preservatives.
  • compositions described herein, in the form of a solid dosage form may be coated with one or more immediate and/or modified release coatings, which further modulate the release of the active agent(s) from the core or central layer.
  • Suitable coatings include, but are not limited to, coatings which are soluble in, or permeable to, the acidic medium of the stomach (i.e. taste mask coatings and immediate release coatings); coatings which are insoluble in the acidic medium of the stomach but are soluble in the neutral environment of the small intestine (i.e. enteric coatings); coatings which are insoluble in the stomach and the environment of the mid to the upper small intestine, but dissolve in the lower small intestine or upper large intestine (i.e. delayed release coatings); and combinations thereof.
  • the dosage forms may also be coated for aesthetic reasons such as to impart a color to the dosage form or to apply a surface finish to the dosage form.
  • Immediate release coatings are formed of a polymer that dissolves within the oral cavity upon contact with saliva or which are insoluble in the neutral pH4 of the oral cavity and which dissolve at the low pH of the stomach.
  • Coatings which dissolve in the mouth may have properties such as mucoadhesion, to prolong contact of the particles with the buccal, sublingual or other oral cavity surfaces to enhance uptake of the active agent(s).
  • mucoadhesive polymers are known and typically are characterized by a high density of carboxylic groups. See for example, U.S. Pat. No. 6,235,313 and U.S. Pat. No. 5,955,096 to Mathiowitz et al.
  • Coatings which dissolve in the stomach are typically used to provide properties such as taste-masking.
  • the cationic polymer Eudragit® E 100 (Rohm Pharma) carries amino groups. Its films are, therefore, insoluble in the neutral medium of saliva, but dissolve by salt formation in the acid environment of the stomach. Such film coatings with a thickness of approximately 10 micrometers can prevent medication with a bitter or unpleasant taste from dissolving in the mouth upon ingestion or during swallowing.
  • the protective film dissolves quickly under the acidic conditions in the stomach allowing for the active agent(s) to be released.
  • the coating composition may include conventional additives, such as plasticizers, pigments, colorants, stabilizing agents, glidants, etc.
  • Suitable coating materials include, but are not limited to, cellulose polymers, such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and methacrylic resins that are commercially available under the trade name Eudragit t (Rohm Pharma), alginates, alkali-soluble acrylic resins, hydroxypropyl methylcellulose phthalate, methacrylate-methacrylic acid co-polymers, polyvinyl acetate phthalate, styrol maleic acid copolymers, copolymers available under the trade name Eudragit® (Rohm Pharma), such as poly(ethylacrylate-methylmethacrylate-triethylammonio
  • copolymers may be used alone, in admixture with each other, and in admixture with plasticizers (for example, triethyl citrate), pigments, and other substances to alter the characteristics of the coating.
  • plasticizers for example, triethyl citrate
  • pigments for example, titanium dioxide
  • other substances to alter the characteristics of the coating.
  • the major components of the coating should be insoluble in, and permeable to, water.
  • a water-soluble substance such as methyl cellulose, to alter the permeability of the coating.
  • the coating materials may be applied as a suspension in an aqueous fluid.
  • the coating composition may include conventional additives, such as plasticizers, pigments, colorants, stabilizing agents, glidants, etc.
  • a plasticizer is normally present to reduce the fragility of the coating, and will generally represent about 10 wt. % to 50 wt. % relative to the dry weight of the polymer.
  • plasticizers are, but not limited to, polyethylene glycol, propylene glycol, triacetin, dimethyl phthalate, diethyl phthalate, dibutyl phthalate, dibutyl sebacate, triethyl citrate, tributyl citrate, triethyl acetyl citrate, castor oil and acetylated monoglycerides.
  • a stabilizing agent may be used to stabilize particles in the dispersion.
  • Typical stabilizing agents are nonionic emulsifiers such as sorbitan esters, polysorbates and polyvinylpyrrolidone. Glidants are recommended to reduce sticking effects during film formation and drying, and will generally represent approximately 25 wt.
  • glidant % to 100 wt, % of the polymer weight in the coating solution.
  • One effective glidant is talc.
  • Other glidants such as magnesium stearate and glycerol monostearates may also be used.
  • Pigments such as titanium dioxide may also be used.
  • Small quantities of an anti-foaming agent, such as a silicone (e.g., simethicone), may also be added to the coating composition.
  • Enteric coated dosage forms can be prepared as described in references such as “Pharmaceutical dosage form tablets”, eds. Liberman et. al. New York, Marcel Dekker, Inc., 1989), “Remington—The science and practice of pharmacy”, 20th ed., Lippincott Williams & Wilkins, Baltimore, Md., 2000, and “Pharmaceutical dosage forms and drug delivery systems”, 6th Edition, Ansel et.al., (Media, P A; Williams and Wilkins, 1995).
  • suitable coating materials include but are not limited to cellulose polymers, such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate; polyvinyl acetate phthalate, acrylic acid polymers and copolymers, and methacrylic resins that are commercially available under the trade name Eudragit 9 (Rohm Pharma). Additionally, the coating material may contain conventional carriers such as plasticizers, pigments, colorants, glidants, stabilization agents, and surfactants.
  • cellulose polymers such as cellulose acetate phthalate, hydroxypropyl cellulose, hydroxypropyl methylcellulose phthalate and hydroxypropyl methylcellulose acetate succinate
  • polyvinyl acetate phthalate acrylic acid polymers and copolymers
  • methacrylic resins that are commercially available under the trade name Eudragit 9 (Rohm Pharma).
  • the coating material may contain conventional carriers such as plasticizer
  • Multilayer tablets may be prepared by compression molding.
  • the core and the one or more barrier layers are prepared separately and then compressed using a multilayer tableting press.
  • the core could be prepared separately with the barrier layers added as a blend, and the composition compressed to form a tablet.
  • the geometric shape of the dosage forms described herein may vary depending on the type of release profile that is desired.
  • the dosage form might consist of a monolithic core.
  • the core may consist of one of more layers containing one or more pharmaceutically active substances in each layer. Dosage forms of this type have been described in U.S. Pat. Nos. 5,626,874, 5,422,123 and 6,027,748 to Conte et al.
  • one or more layers may contain no active agent(s).
  • Each layer may contain the same or different release-controlling materials and excipients.
  • the dosage form may be a multiparticulate system. Each particle may contain the same or different pharmaceutically active substance and the same or different release-controlling materials and other adjuvants.
  • the core is multilayered, e.g. having two or three layers, one or more of which contains active agent(s) and the other layers contain no active agent(s).
  • the dosage form comprises a core consisting of three layers wherein an inner layer contains active agent(s) and the two outer layers do not contain active agent(s).
  • the formulations can be coated with a film coat that at least partially overcoats the core using techniques well known in the art.
  • the coatings can be applied as a solid or as an aqueous suspension or organic solution. Suitable techniques for applying the coating include, but are not limited to, spray coating, pan coating, fluid bed coating, and compression coating.
  • the dosage forms described herein can be administered to treat a variety of diseases or disorders. Although preferred patients are human, typically any mammal including domestic animals such as dogs and cats, may also be treated.
  • the dosage forms are generally administered orally in the form of a tablet or caplet.
  • the dosage forms can be administered in a single dose, an escalating dose, or administered at an elevated dosage which is then decreased to a lower dosage after a particular circulating blood concentration of the active agent(s) has been achieved.
  • One of skill in the art would be able to choose administration protocols and determine appropriate dosing regimes based on bioavailability and half-life of the pharmaceutically active substance to be administered.
  • Appropriate dosages of the substance can be determined by one of skill in the art using routine experimentation and standard techniques utilizing dosages currently approved, Intra-patient variability is known in the art depending on the severity of symptoms and dosages are commonly adjusted to exact a particular therapeutic effect in a particular patient.
  • the active agent can be administered in amounts between about 0.001 to 100 mg/kg of body weight, preferably 0.01 to 10 mg/kg, more preferably 0.1 to 10 mg/kg.
  • the active agent can be administered at a dosage of between about 0.001 to 100 mg/kg of body weight of the patient, preferably 0.01 mg to 10 mg/kg, more preferably 0.1 to 1.0 mg/kg.
  • Preferred daily doses of a calcium channel blocker are approximately 1-100 mg, preferably 2.5 mg to 50 mg to treat cardiovascular disorders such as hypertension, angina and cardiac arrhythmia.
  • release-controlling matrix By employing a mixture of enteric material(s) and hydrophilic material(s) to form a release-controlling matrix one can obtain release profiles characterized by the initial slow release of a drug substance, which over time as the dosage form descends in the GI tract, leads to increasing release rates in response to changes in pH. Such releases profiles may be highly desirable when it is necessary to release the majority of the dose of an active substance in the lower GI tract.
  • lower GI tract is meant the ileum and large intestine.
  • the term “ileum” refers to the third part of the small intestine that continues to the duodenum and the jejunum.
  • large intestine refers to a site consisting of the cecum, colon and rectum.
  • cecum refers to a blind sack starting from the large intestine and in one end of which the ileum opens.
  • the dosage forms described herein can be formulated to provide a variety of pharmacokinetic release profiles designed to target the release of active agent(s) at a higher release rate at a particular absorption site in the lower GI tract. As such, the use of these dosage forms may diminish or eliminate unwanted side effects of many active agents. They may also render active agents efficacious, yet reduced in dose, compared with known formulations of those active substances.
  • the compositions described herein provide an increased bioavailability (as measured by area under the drug plasma concentration-time curve (AUC)) as compared to the same dose of a calcium channel blocker, such as nisoldipine, in a reference formulation containing a slow release core and an immediate release coating (coat-core).
  • AUC drug plasma concentration-time curve
  • the compositions provide an increase in bioavailability of nisoldipine as compared to the same dose of drug in SULAR®.
  • the compositions contain a reduced dose of nisoldipine, but exhibit a similar pharmacokinetic profile as SULAR®.
  • a trilayer tablet containing 40 mg nisoldipine (Formulation A) exhibited a roughly 16% increase in the AUC last compared to SULAR® 40 mg.
  • the dose of nisoldipine in the trilayer tablet can be reduced by approximately 15-17%, or 16% (i.e. to 34 mg) and still provide an effective amount of the drug.
  • the 10 mg, 20 mg, 30 mg, and 40 mg dosage strengths of SULAR® can be replaced with reduced, bioequivalent dosage strengths (for example, 8.5 mg, 17 mg, 25.5 mg, and 34 mg). This may result in lower manufacturing costs due to the lower doses required to obtain the desired therapeutic effect.
  • compositions described herein contain one or more controlled release elements in an amount effective to provide a controlled release of the calcium channel blocker, the composition providing a T max of the calcium channel blocker from about 9 to about 20 hours and an AUC last of the calcium channel blocker from about 48 to about 63 hr*ng/ml under fasting conditions based on a 40 mg dose.
  • compositions described herein contain one or more controlled release elements in an amount effective to provide a controlled release of the calcium channel blocker, the composition providing a T max of the calcium channel blocker from about 9 to about 20 hours and a Cmax of the calcium channel blocker from about 2.75 to about 4 ng/mL under fasting conditions based on a 40 mg dose.
  • Formulation A Three different formulations, each of which contained 40 mg of Nisoldipine, were prepared.
  • the formulations are identified as Formulation A, Formulation B, and Formulation C and are described in Tables 1-3.
  • Formulation C was coated with an enteric coating (5% weight gain) containing a combination of Eudragit® S100 (methacrylic acid copolymer type B) and Eudragit® L100 (methacrylic acid copolymer type A).
  • Formulations A and B were coated with an OPADRY® II seal coat available from Colorcon, West Point, Pa.
  • Nisoldipine and sodium lauryl sulfate were mixed in a high shear mixer for two minutes. Lactose monohydrate, povidone, methacrylic acid copolymer (type B), and hypromellose type 2208 (Methocel K4M) were added to the mixer and mixed for ten minutes.
  • the binding solution was prepared by dissolving povidone in purified water and adding sodium lauryl sulfate. The mixture was mixed in a suitable tank and left to rest until defoaming was complete.
  • the binding solution was added to the high shear mixer containing the mixture of step 1 and mixed briefly for two minutes.
  • the resulting granulation was kneaded and transferred to a fluid bed dryer and dried until an LOD below 2.5% was obtained. After drying, the granulation was milled with an oscillatory mill.
  • Magnesium stearate was premixed manually with 5% of the mixture from step 4. The premix was added to the granulation in a diffusion blender and mixed for ten minutes.
  • Lactose monohydrate, glyceryl behenate, ferric oxide (yellow), povidone, hypromellose type 2910 (Methocel E4M), and optionally hypromellose phthalate were added to a high shear mixer and mixed for six minutes.
  • the granulation was transferred to a fluid bed dryer and dried until an LOD below 2.5% was obtained. After drying, the granulation was milled on an oscillatory mill.
  • Magnesium stearate was premixed manually with 5% of the mixture from step 4. The premix was added to the granulation in a diffusion blender and mixed for ten minutes.
  • the central layer and the barrier layers were loaded into a HATA multi-layer tablet press and pressed to form the trilayer tablets.
  • the film coatings are applied at a target of 5% weight gain on a 563 mg tablet.
  • Opadry® II film coating compositions were obtained from Colorcon, West Point Pa. Four different coating compositions were used: 49B97383 Beige, 49B97382 Beige, 49B92439 Yellow, and 49B97379 Beige. All of the film coat compositions contain polydextrose FCC, HPMC 2910/hypromellose 3 cP, HPMC 2910/hypromellose 6 cP, titanium dioxide, HPMC 2910/hypromellose 15 cP, macrogol/PEG, iron oxide yellow, and carnauba wax. The coating compositions vary in the presence or absence of iron oxide black, iron oxide red, and FD&C yellow #5/Tartrazine Aluminum Lake. The tablets were coated as directed by the manufacturer.
  • Methacrylic acid copolymer type B (Eudragit S100) was added slowly to a vortex of purified water and mixed until dissolved.
  • step 3 The 1N potassium hydroxide solution of step 1 was added to the solution of step 2 and the mixture was stirred gently.
  • Triethyl citrate was added to the solution of step 3 and stirred until the mixture was homogeneous.
  • Steps 1-4 were repeated using methacrylic acid copolymer type A (Eudragit L100) to form a homogeneous mixture.
  • step 6 The solution of step 4 was added to a mixing vessel and stirred slowly.
  • the solution of step 5 was added to the vessel and the mixture was stirred for the required period of time.
  • formulations A-C described in Example 1 were compared to those of a reference formulation (Formulation D).
  • the reference formulation was SULAR® Nisoldipine Extended Release (40 mg).
  • SULAR® is a coat-core formulation consisting of a core containing Nisoldipine, coated with an immediate release coating which also contains Nisoldipine.
  • the components of SULAR®, and their concentrations, are given in Table 4.
  • Example I Thirty-two healthy adults participated in the comparison of the three formulations of nisoldipine 40 mg tablets described in Example I versus SULAR®. 31 subjects completed the study. Subjects received the assigned treatment during the first period and received the alternate treatment during the subsequent periods according to the randomization scheme. Dosing days were separated by a washout period of at least 7 days. An equal number of subjects were randomly assigned to each possible sequence of treatments. Drug administration consisted of an oral dose of the formulations described in Example 1 and SULAR® under fasting conditions.
  • Plasma samples were analyzed by CEDRA Corporation using a validated LC-MS-MS procedure with a lower limit of quantification of 0.0150 ng/mL for nisoldipine. Data were stored in the Watson LIMS System (Thermio Electron Corporation Version 6.4.0.02).
  • concentration-time data were transferred from Watson directly to WinNonlin (Enterprise Version 4.0, Pharsight, Cary, N.C.) using the Custom Query Builder option for analysis. Data were analyzed by non-compartmental methods in WinNonlin. Concentration-time data that were BLQ ( ⁇ 0.0150 ng/mL) were treated as zero (0.00 ng/mL) in the data summarization and descriptive statistics. In the pharmacokinetic analysis, BLQ concentrations were treated as zero from time-zero up to the time at which the first quantifiable concentration was observed; embedded and/or terminal BLQ concentrations were treated as “missing”. Full precision concentration data were used for all pharmacokinetic and statistical analyses.
  • Treatment D Test Formulation #1 Reference Product Parameter n Mean SD CV % n Mean SD CV % T max (hr) 31 9.42 5.57 59.16 32 8.12 7.34 90.47 T lag (hr) 31 0.03 0.18 556.78 32 0.13 0.71 565.69 C max (ng/mL) 31 4.03 2.51 62.22 32 3.49 1.52 43.42 AUC last 31 62.61 24.53 39.18 32 53.46 23.26 43.51 (hr * ng/mL) AUC inf (hr * ng/mL) 29 72.84 30.97 42.52 30 68.21 43.33 63.52 AUC Extrap (%) 29 12.17 11.27 92.55 30 14.00 15.84 113.11 ⁇ z (hr ⁇ 1 ) 29 0.0600 0.0247 41.06 30 0.0580 0.0238 41.02 T 1/2 (hr) 29 14.23 8.
  • the objective of this study was to compare the food effect of the Formulation A described in Example versus the food effect of the Sular® market formulation.
  • the pharmacokinetic data for these two formulations from Example 2 under fasting conditions were used as a reference.
  • the same 32 subjects from Example 2 were enrolled in the food effect study.
  • Table 11 shows statistical analysis of the log-transformed systemic parameters of nisoldipine after test formulation A (Treatment E) and the reference product (Treatment F) under fed conditions.
  • TABLE 9 Statistical Analysis of the Non-Transformed Pharmacokinetic Parameters of Nisoldipine after Test Formulation #1 (Treatment E) and Reference Product (Treatment F) under Fed Conditions Ratio (%) 90% Confidence Dependent Least Squares Mean (Test/ Interval Variable Test Reference Reference) Lower Upper Power C max 9.0795 10.1485 89.47 63.66 115.27 0.3547 AUC last 46.7358 49.9013 93.66 77.56 109.75 0.6596 AUC inf 48.9166 52.8817 92.50 77.06 107.95 0.6910 T max 6.1372 6.2904 97.56 81.34 113.79 0.6534 T lag 0.0769 0.1154 66.67 ⁇ 65.04 198.37 0.1101 ⁇
  • Table 5 shows that the AUC last for formulation A is approximately 17% higher than the AUC last for the reference formulation having the same dosage of nisoldipine. This suggests that the dose of nisoldipine in formulation A can be reduced by approximately 16% and still exhibit a pharmacokinetic profile similar to the reference formulation.
  • Formulations containing 8.5, 17, 25.5, and 34 mg of Nisoldipine in the core were prepared based on the procedures described in Example 1. These dosages represent approximately 16% less than 10 mg, 20 mg, 30 mg, and 40 mg, respectively. The components of each formulation, and their concentrations, are shown in Tables 10-13.
  • Test product “Treatment E” is Geomatrix® 16-E nisoldipine extended-release tablet administered in one 34 mg tablet.
  • Reference product “Treatment F” is Sular® extended-release tablet administered in one 40 mg tablet.
  • Blood samples (1 ⁇ 6 mL, 2 ⁇ 6 mL) were collected in vacutainer tubes containing K 2 -EDTA as a preservative at pre-dose (0) and at 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7,5, 9.0, 10.5, 12.0, 14.0, 18.0, 24.0, 26.0, 28.0, 30.0, 36.0, 48.0, 60.0, and 72.0 hours after dosing during each study period.
  • Plasma samples were analyzed for nisoldipine by CEDRA Corporation using validated LC-MS-MS procedures. The methods were validated for ranges of 0.0150 to 10.0 ng/mL and 1.00 to 100 pg/mL, based on the analysis of 0.250 mL and 1.00 mL of plasma, respectively.
  • Concentration-time data were transferred from Watson LIMS directly to WinNonlin Enterprise Edition (Version 4.0, Pharsight Corporation) using the Custom Query Builder option for analysis. Data were analyzed by noncompartmental methods in WinNonlin. Concentration-time data that were below the limit of quantification (BLQ) were treated as zero in the data summarization and descriptive statistics. In the pharmacokinetic analysis, BLQ concentrations were treated as zero from time-zero up to the time at which the first quantifiable concentration was observed; embedded and/or terminal BLQ concentrations were treated as “missing.” Full precision concentration data (not rounded to three significant figures) and actual sample times were used for all pharmacokinetic and statistical analyses.
  • Plasma concentration-time data and pharmacokinetic parameters were summarized by treatment. Since subjects were scheduled to receive each treatment on two occasions, descriptive statistics by treatment are based on 93 to 95 observations. Quantifiable pre-dose concentrations were observed for some subjects. However, since the pre-dose concentrations were well below 5% of C max for these subjects after a given treatment, the pre-dose concentrations were included in all pharmacokinetic analyses without adjustment.
  • the 90% confidence interval for comparing the maximum exposure, based on ln(C max ), is within the accepted 80% to 125% limits.
  • the 90% confidence intervals for comparing total systemic exposure, based on ln(AUC last ) and ln(AUC inf ), are within the accepted 80% to 125% limits. Therefore, the test formulation of Geomatrix® 16-E, 34 mg tablets is bioequivalent to the reference product, Sular® 40 mg tablets, under fasting conditions.
  • FIG. 2 shows the mean nisoldipine concentration time profiles after administration of test formulation 16-E (Sular Geomatrix-Formulation E, 34 mg nisoldipine) and the referenced product (Sular, Formulation F, 40 mg nisoldipine).
  • Test product “Treatment G” is Geomatrix® nisoldipine extended-release tablet administered in one 8.5 mg tablet.
  • Reference product “Treatment A” is Sular® extended-release tablet administered in one 10 mg tablet.
  • one 6 mL blood sample was obtained within 60 minutes prior to each dose administration and following each dose at selected times through 36 hours post-dose.
  • Two 6 mL blood samples were obtained at 48, 60, and 72 hours post-dose.
  • a total of 96 PK blood samples were to be collected from each subject, 24 samples in each of four separate study periods. Forty-Nine (49) of the 52 subjects enrolled completed at least two periods of the study.
  • Blood samples (1 ⁇ 6 mL, 2 ⁇ 6 mL) were collected in vacutainer tubes containing K 2 -EDTA as a preservative at pre-dose (0) and at 1.0, 2.0, 3.0, 4.0, 5.0, 6.0, 7.5, 9.0, 10.5, 12.0, 14.0, 18.0, 24.0, 26.0, 28.0, 30.0, 36.0, 48.0, 60.0, and 72.0 hours after dosing during each study period.
  • Plasma samples were analyzed for nisoldipine by CEDRA Corporation using validated LC-MS-MS procedures. The methods were validated for ranges of 0.0 150 to 10.0 ng/mL and 1.00 to 100 pg/mL, based on the analysis of 0.250 mL and 1.00 mL of plasma, respectively.
  • Concentration-time data were transferred from Watson LIMS directly to WinNonlin Enterprise Edition (Version 4.0, Pharsight Corporation) using the Custom Query Builder option for analysis. Data were analyzed by noncompartmental methods in WinNonlin. Concentration-time data that were below the limit of quantification (BLQ) were treated as zero in the data summarization and descriptive statistics. In the pharmacokinetic analysis, BLQ concentrations were treated as zero from time-zero up to the time at which the first quantifiable concentration was observed; embedded and/or terminal BLQ concentrations were treated as “missing.” Full precision concentration data (not rounded to three significant figures) and actual sample times were used for all pharmacokinetic and statistical analyses.
  • Plasma concentration-time data and pharmacokinetic parameters were summarized by treatment. Since subjects were scheduled to receive each treatment on two occasions, descriptive statistics by treatment are based on 96 or 94 observations. Mean concentration-time data are shown in FIG. 3. Results of the pharmacokinetic and statistical analyses are shown below in Table 15 and Table 16.
  • the 90% confidence interval for comparing the maximum exposure, based on ln(C max ), is within the accepted 80% to 125% limits.
  • the 90% confidence intervals for comparing total systemic exposure, based on ln(AUC last ) and ln(AUC inf ), are within the accepted 80% to 125% limits. Therefore, the test formulation, Geomatrix 8.5 mg tablets, is bioequivalent to the reference product, Sular extended-release 10 mg tablets, under fasting conditions.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
US11/847,012 2006-08-30 2007-08-29 Controlled Release Formulations Abandoned US20080057123A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/847,012 US20080057123A1 (en) 2006-08-30 2007-08-29 Controlled Release Formulations

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US82404306P 2006-08-30 2006-08-30
US82405406P 2006-08-30 2006-08-30
US11/847,012 US20080057123A1 (en) 2006-08-30 2007-08-29 Controlled Release Formulations

Publications (1)

Publication Number Publication Date
US20080057123A1 true US20080057123A1 (en) 2008-03-06

Family

ID=38686769

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/846,896 Active 2029-01-31 US9101544B2 (en) 2006-08-30 2007-08-29 Controlled release nisoldipine compositions
US11/847,012 Abandoned US20080057123A1 (en) 2006-08-30 2007-08-29 Controlled Release Formulations
US14/796,248 Active US9622980B2 (en) 2006-08-30 2015-07-10 Controlled release compositions

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US11/846,896 Active 2029-01-31 US9101544B2 (en) 2006-08-30 2007-08-29 Controlled release nisoldipine compositions

Family Applications After (1)

Application Number Title Priority Date Filing Date
US14/796,248 Active US9622980B2 (en) 2006-08-30 2015-07-10 Controlled release compositions

Country Status (10)

Country Link
US (3) US9101544B2 (enExample)
EP (2) EP2063871A1 (enExample)
JP (3) JP2010501607A (enExample)
KR (2) KR101575679B1 (enExample)
AU (2) AU2007291506A1 (enExample)
CA (2) CA2662123C (enExample)
ES (1) ES2547226T5 (enExample)
MX (2) MX2009002236A (enExample)
WO (2) WO2008025532A1 (enExample)
ZA (1) ZA200901688B (enExample)

Cited By (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080063711A1 (en) * 2006-08-30 2008-03-13 Jagotec Ag Controlled Release Nisoldipine Compositions
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US20100222312A1 (en) * 2009-01-26 2010-09-02 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
US20100247646A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Extended release tablets of nisoldipine
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
US20100285125A1 (en) * 2009-05-07 2010-11-11 Padma Venkitachalam Devarajan Delivery system for poorly soluble drugs
US20110076325A1 (en) * 2007-08-13 2011-03-31 Abuse Deterrent Pharmaceutical, Llc Abuse resistant drugs, method of use and method of making
US20110091563A1 (en) * 2008-03-11 2011-04-21 Takeda Pharmaceutical Company Limited Orally-disintergrating solid preparation
US20110217373A1 (en) * 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical compositions of guanfacine hydrochloride
WO2013007698A1 (en) 2011-07-08 2013-01-17 Gosforth Centre (Holdings) Pty Ltd Pharmaceutical composition for neurological disorders
US20130252956A1 (en) * 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9616030B2 (en) 2013-03-15 2017-04-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9707180B2 (en) 2010-12-23 2017-07-18 Purdue Pharma L.P. Methods of preparing tamper resistant solid oral dosage forms
US9867791B2 (en) 2009-12-02 2018-01-16 Adamas Pharma, Llc Method of administering amantadine prior to a sleep period
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
US10406029B2 (en) 2001-04-07 2019-09-10 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
US20200030242A1 (en) * 2016-02-05 2020-01-30 Entrega Inc. Oral dosage form with drying agent for delivery of active agent
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US11065213B2 (en) 2017-08-24 2021-07-20 Adamas Pharma, Llc Amantadine compositions and preparations thereof
US20220047515A1 (en) * 2018-12-14 2022-02-17 Dpl Pharma S.P.A. Solid oral pharmaceutical compositions for administration of mesalazine or derivatives thereof
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US20220331257A1 (en) * 2019-03-01 2022-10-20 Avadel Legacy Pharmaceuticals, Llc Liquid pharmaceutical compositions with stable drug release profiles
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US12201557B2 (en) 2009-05-18 2025-01-21 Dose Medical Corporation Drug eluting ocular implant and method of treating an ocular disorder
US12419783B2 (en) 2010-11-24 2025-09-23 Glaukos Corporation Drug eluting ocular implant
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101632079B1 (ko) * 2007-07-23 2016-06-20 파마덴 에스.에이. 디히드로피리딘 칼슘 채널 길항제를 함유하는 약제학적 조성물 및 그것의 제조방법
CA2735460A1 (en) * 2008-08-29 2010-03-04 The Uab Research Foundation Novel anti-arrhythmia agent
KR20100069170A (ko) * 2008-12-16 2010-06-24 삼일제약주식회사 라시디핀 함유 과립 및 이를 포함하는 약학 조성물
WO2011006012A1 (en) 2009-07-08 2011-01-13 Charleston Laboratories Inc. Pharmaceutical compositions
EP2561892B1 (en) * 2010-03-31 2015-05-06 Mochida Pharmaceutical Co., Ltd. Easily dosable solid preparation
WO2013046453A1 (ja) 2011-09-30 2013-04-04 持田製薬株式会社 易服用性固形製剤
HK1216240A1 (zh) 2012-11-14 2016-10-28 W. R. Grace & Co.-Conn. 含有生物活性材料与无序无机氧化物的组合物
KR102170642B1 (ko) * 2013-11-14 2020-10-27 코웨이 주식회사 기능성 제재 공급기 및 이를 포함하는 연수기
JP2019507181A (ja) 2016-03-04 2019-03-14 チャールストン ラボラトリーズ，インコーポレイテッド 医薬組成物
JP6983868B2 (ja) 2016-04-22 2021-12-17 レセプター・ホールディングス・インコーポレイテッド 即効性の植物由来医薬化合物及び栄養補給剤
EA201892396A1 (ru) 2016-12-02 2019-04-30 Ресептор Лайф Сайенсиз, Инк. Быстродействующие растительные лекарственные соединения и биологически активные добавки
CA3067332A1 (en) 2017-06-16 2018-12-20 The Doshisha Mtor-inhibitor-containing medicine for treating or preventing ophthalmic symptoms, disorders, or diseases, and application thereof
WO2018230713A1 (ja) * 2017-06-16 2018-12-20 学校法人同志社 カスパーゼ阻害活性を有する化合物、これらの化合物を含む、角膜内皮の症状、障害または疾患を治療または予防するための医薬およびその応用
MY204588A (en) * 2017-10-25 2024-09-05 Chiesi Farm Spa Delayed release deferiprone tablets and methods of using the same
AU2019385420A1 (en) 2018-11-19 2021-07-08 Spoke Sciences, Inc. N-acylated fatty amino acids to reduce absorption variability in cannabinoid based compositions
CN114630656B (zh) * 2019-08-26 2025-03-21 埃斯普投资有限公司 黏膜黏附剂组合物及其使用方法
JP2024541083A (ja) * 2021-11-19 2024-11-06 ポール バーリア スシュマ フラボキサートの制御放出製剤及びその調製方法

Citations (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892741A (en) * 1987-06-24 1990-01-09 Bayer Aktiengesellschaft Press coated DHP tablets
US4933186A (en) * 1987-08-11 1990-06-12 Bayer Aktiengesellschaft Dihydropyridine depot formulation
US4966772A (en) * 1988-04-29 1990-10-30 Bayer Aktiengesellschaft DHP delayed release preparation
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US5071642A (en) * 1986-10-23 1991-12-10 Dr. Rentschler Arzneimittel Gmbh & Co. Dihydropyridine containing compositions
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
US5422123A (en) * 1989-12-14 1995-06-06 Jagotec Ag Tablets with controlled-rate release of active substances
US5439687A (en) * 1992-02-17 1995-08-08 Siegfried Pharma Ag Dosage forms having zero-order dihydropyridine calcium antagonist release
US5626874A (en) * 1993-11-30 1997-05-06 Ekita Investments N.V. Controlled release pharmaceutical tablet having lenticular form
US5667804A (en) * 1995-02-24 1997-09-16 Alza Corporation Banded prolonged release active agent dosage form
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6027748A (en) * 1997-01-08 2000-02-22 Jagotec Ag Pharmaceutical tablet, completely coated, for controlled release of active principles that present problems of bio-availability linked to gastro-intestinal absorption
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US6221395B1 (en) * 1997-09-03 2001-04-24 Jagotec Ag Controlled release pharmaceutical tablets containing an active principle of low water solubility
US6235313B1 (en) * 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6294200B1 (en) * 1996-02-06 2001-09-25 Jagotec Ag Pharmaceutical tablet suitable to deliver the active substance in subsequent and predeterminable times
US6387404B2 (en) * 1993-11-23 2002-05-14 Euro-Celtique S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US6923988B2 (en) * 1999-11-23 2005-08-02 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6962717B1 (en) * 1999-01-29 2005-11-08 Disphar International B.V. Pharmaceutical compositions

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
IT1251153B (it) * 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
GB9402203D0 (en) * 1994-02-04 1994-03-30 Smithkline Beecham Plc Pharmaceutical formulation
JP2849047B2 (ja) * 1994-12-19 1999-01-20 大正薬品工業株式会社 ジクロフェナクナトリウム持続性製剤およびその製法
IT1282650B1 (it) 1996-02-19 1998-03-31 Jagotec Ag Compressa farmaceutica,caratterizzata da elevato aumento di volume a contatto con liquidi biologici
DE19906290A1 (de) * 1999-02-15 2000-08-17 Falk Pharma Gmbh Arzneimittel zur Behandlung bzw. Prävention von Darmkrebs
AR030557A1 (es) * 2000-04-14 2003-08-27 Jagotec Ag Una tableta en multicapa de liberacion controlada y metodo de tratamiento
DE10115216A1 (de) * 2001-03-28 2002-10-10 Bosch Gmbh Robert Kraftstoffeinspritzventil für Brennkraftmaschinen
EP2359817B1 (en) * 2003-03-28 2018-01-10 Sigmoid Pharma Limited Solid oral dosage form containing seamless microcapsules
JP2005132803A (ja) * 2003-10-31 2005-05-26 Ono Pharmaceut Co Ltd 胃内滞留固形剤
WO2005070462A2 (en) 2004-01-12 2005-08-04 Sepracor, Inc. Compositions comprising (s)-amlodipine and an angiotensin receptor blocker and methods of their use
DE602005010899D1 (de) 2004-09-27 2008-12-18 Sigmoid Pharma Ltd Mikrokapseln mit einem methylxanthin und einem kortikosteroid
MX2009002236A (es) 2006-08-30 2009-03-13 Jagotec Ag Formulaciones de dosis oral de liberacion controlada que comrpenden un nucleo y una o mas capas de barrera.

Patent Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071642A (en) * 1986-10-23 1991-12-10 Dr. Rentschler Arzneimittel Gmbh & Co. Dihydropyridine containing compositions
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4968508A (en) * 1987-02-27 1990-11-06 Eli Lilly And Company Sustained release matrix
US4892741A (en) * 1987-06-24 1990-01-09 Bayer Aktiengesellschaft Press coated DHP tablets
US4933186A (en) * 1987-08-11 1990-06-12 Bayer Aktiengesellschaft Dihydropyridine depot formulation
US4966772A (en) * 1988-04-29 1990-10-30 Bayer Aktiengesellschaft DHP delayed release preparation
US5422123A (en) * 1989-12-14 1995-06-06 Jagotec Ag Tablets with controlled-rate release of active substances
US5209933A (en) * 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
US5439687A (en) * 1992-02-17 1995-08-08 Siegfried Pharma Ag Dosage forms having zero-order dihydropyridine calcium antagonist release
US6235313B1 (en) * 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6387404B2 (en) * 1993-11-23 2002-05-14 Euro-Celtique S.A. Immediate release tablet cores of insoluble drugs having sustained-release coating
US5626874A (en) * 1993-11-30 1997-05-06 Ekita Investments N.V. Controlled release pharmaceutical tablet having lenticular form
US6103263A (en) * 1994-11-17 2000-08-15 Andrx Pharmaceuticals, Inc. Delayed pulse release hydrogel matrix tablet
US5667804A (en) * 1995-02-24 1997-09-16 Alza Corporation Banded prolonged release active agent dosage form
US6020000A (en) * 1995-02-24 2000-02-01 Alza Corporatiton Banded prolonged release active agent dosage form
US6083532A (en) * 1995-03-01 2000-07-04 Duramed Pharmaceuticals, Inc. Sustained release formulation containing three different types of polymers and tablet formed therefrom
US5736159A (en) * 1995-04-28 1998-04-07 Andrx Pharmaceuticals, Inc. Controlled release formulation for water insoluble drugs in which a passageway is formed in situ
US5900425A (en) * 1995-05-02 1999-05-04 Bayer Aktiengesellschaft Pharmaceutical preparations having controlled release of active compound and processes for their preparation
US5783212A (en) * 1996-02-02 1998-07-21 Temple University--of the Commonwealth System of Higher Education Controlled release drug delivery system
US6294200B1 (en) * 1996-02-06 2001-09-25 Jagotec Ag Pharmaceutical tablet suitable to deliver the active substance in subsequent and predeterminable times
US5955096A (en) * 1996-06-25 1999-09-21 Brown University Research Foundation Methods and compositions for enhancing the bioadhesive properties of polymers using organic excipients
US6027748A (en) * 1997-01-08 2000-02-22 Jagotec Ag Pharmaceutical tablet, completely coated, for controlled release of active principles that present problems of bio-availability linked to gastro-intestinal absorption
US5922352A (en) * 1997-01-31 1999-07-13 Andrx Pharmaceuticals, Inc. Once daily calcium channel blocker tablet having a delayed release core
US6096339A (en) * 1997-04-04 2000-08-01 Alza Corporation Dosage form, process of making and using same
US6221395B1 (en) * 1997-09-03 2001-04-24 Jagotec Ag Controlled release pharmaceutical tablets containing an active principle of low water solubility
US6962717B1 (en) * 1999-01-29 2005-11-08 Disphar International B.V. Pharmaceutical compositions
US6923988B2 (en) * 1999-11-23 2005-08-02 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US6866866B1 (en) * 2000-11-03 2005-03-15 Andrx Labs, Llc Controlled release metformin compositions
US20040198789A1 (en) * 2003-02-28 2004-10-07 Recordati Ireland Limited Lercanidipine/ARB/diuretic therapeutic combinations

Cited By (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10406029B2 (en) 2001-04-07 2019-09-10 Glaukos Corporation Ocular system with anchoring implant and therapeutic agent
US9504699B2 (en) 2006-08-03 2016-11-29 Hznp Limited Delayed-release glucocorticoid treatment of rheumatoid disease
US8920838B2 (en) 2006-08-03 2014-12-30 Horizon Pharma Ag Delayed-release glucocorticoid treatment of rheumatoid disease
US20080063711A1 (en) * 2006-08-30 2008-03-13 Jagotec Ag Controlled Release Nisoldipine Compositions
US9622980B2 (en) 2006-08-30 2017-04-18 Jagotec Ag Controlled release compositions
US9101544B2 (en) 2006-08-30 2015-08-11 Jagotec Ag Controlled release nisoldipine compositions
US10736850B2 (en) 2007-08-13 2020-08-11 Ohemo Life Sciences Inc. Abuse resistant oral opioid formulations
US10688051B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release oxycodone, method of use, and method of making
US7955619B2 (en) 2007-08-13 2011-06-07 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110150971A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110150991A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110150969A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110150990A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110150970A1 (en) * 2007-08-13 2011-06-23 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110159090A1 (en) * 2007-08-13 2011-06-30 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110159089A1 (en) * 2007-08-13 2011-06-30 Inspirion Delivery Technologies, Llc Abuse resistant drugs, method of use and method of making
US20110076325A1 (en) * 2007-08-13 2011-03-31 Abuse Deterrent Pharmaceutical, Llc Abuse resistant drugs, method of use and method of making
US10736852B2 (en) 2007-08-13 2020-08-11 OHEMO Life Sciences, Inc. Abuse resistant oral opioid formulations
US10729657B2 (en) 2007-08-13 2020-08-04 Ohemo Life Sciences Inc. Abuse resistant forms of extended release morphine, method of use and method of making
US10729656B2 (en) 2007-08-13 2020-08-04 Ohemo Life Sciences Inc. Abuse resistant forms of immediate release oxycodone, method of use and method of making
US11045422B2 (en) 2007-08-13 2021-06-29 Oheno Life Sciences, Inc. Abuse resistant drugs, method of use and method of making
US10736851B2 (en) 2007-08-13 2020-08-11 Ohemo Life Sciences Inc. Abuse resistant forms of extended release morphine with oxycodone, method of use and method of making
US10702480B2 (en) 2007-08-13 2020-07-07 OHEMO Life Sciences, Inc. Abuse resistant forms of extended release morphine, method of use and method of making
US10688053B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release hydrocodone, method of use and method of making
US10695298B2 (en) 2007-08-13 2020-06-30 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release hydromorphone, method of use and method of making
US10688054B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release morphine, method of use and method of making
US10688055B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences, Llc Abuse resistant forms of extended release morphine, method of use and method of making
US10688052B2 (en) 2007-08-13 2020-06-23 Inspirion Delivery Sciences Llc Abuse resistant forms of extended release oxymorphone, method of use and method of making
US20110091563A1 (en) * 2008-03-11 2011-04-21 Takeda Pharmaceutical Company Limited Orally-disintergrating solid preparation
US9241910B2 (en) 2008-03-11 2016-01-26 Takeda Pharmaceutical Company Limited Orally-disintegrating solid preparation
WO2010015029A1 (en) 2008-08-06 2010-02-11 Gosforth Centre (Holdings) Pty Ltd Compositions and methods for treating psychiatric disorders
US20100222312A1 (en) * 2009-01-26 2010-09-02 Nitec Pharma Ag Delayed-release glucocorticoid treatment of asthma
US20100247646A1 (en) * 2009-03-26 2010-09-30 Ranbaxy Laboratories Limited Extended release tablets of nisoldipine
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
US20100285125A1 (en) * 2009-05-07 2010-11-11 Padma Venkitachalam Devarajan Delivery system for poorly soluble drugs
US12201557B2 (en) 2009-05-18 2025-01-21 Dose Medical Corporation Drug eluting ocular implant and method of treating an ocular disorder
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478504B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Drug eluting ocular implants
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US12376989B2 (en) 2009-05-18 2025-08-05 Glaukos Corporation Drug eluting ocular implants and methods of treating an ocular disorder
US12201555B2 (en) 2009-05-18 2025-01-21 Dose Medical Corporation Drug eluting ocular implant
US11426306B2 (en) 2009-05-18 2022-08-30 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US11197835B2 (en) 2009-12-02 2021-12-14 Adamas Pharma, Llc Method of administering amantadine prior to a sleep period
US9867793B2 (en) 2009-12-02 2018-01-16 Adamas Pharma, Llc Method of administering amantadine prior to a sleep period
US9867791B2 (en) 2009-12-02 2018-01-16 Adamas Pharma, Llc Method of administering amantadine prior to a sleep period
US9867792B2 (en) 2009-12-02 2018-01-16 Adamas Pharma, Llc Method of administering amantadine prior to a sleep period
US9877933B2 (en) 2009-12-02 2018-01-30 Adamas Pharma, Llc Method of administering amantadine prior to a sleep period
US20110217373A1 (en) * 2010-01-29 2011-09-08 Kumaravel Vivek Extended release pharmaceutical compositions of guanfacine hydrochloride
US20130252956A1 (en) * 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
US12419783B2 (en) 2010-11-24 2025-09-23 Glaukos Corporation Drug eluting ocular implant
US9872837B2 (en) 2010-12-22 2018-01-23 Purdue Pharma L.P. Tamper resistant controlled release dosage forms
US9750703B2 (en) 2010-12-22 2017-09-05 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US10966932B2 (en) 2010-12-22 2021-04-06 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US11911512B2 (en) 2010-12-22 2024-02-27 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9861584B2 (en) 2010-12-22 2018-01-09 Purdue Pharma L.P. Tamper resistant controlled release dosage forms
US9744136B2 (en) 2010-12-22 2017-08-29 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9572779B2 (en) 2010-12-22 2017-02-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US11590082B2 (en) 2010-12-22 2023-02-28 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9393206B2 (en) 2010-12-22 2016-07-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9895317B2 (en) 2010-12-23 2018-02-20 Purdue Pharma L.P. Tamper resistant solid oral dosage forms
US9707180B2 (en) 2010-12-23 2017-07-18 Purdue Pharma L.P. Methods of preparing tamper resistant solid oral dosage forms
US10245178B1 (en) 2011-06-07 2019-04-02 Glaukos Corporation Anterior chamber drug-eluting ocular implant
WO2013007698A1 (en) 2011-07-08 2013-01-17 Gosforth Centre (Holdings) Pty Ltd Pharmaceutical composition for neurological disorders
US10478504B2 (en) 2013-02-05 2019-11-19 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9579389B2 (en) 2013-02-05 2017-02-28 Purdue Pharma L.P. Methods of preparing tamper resistant pharmaceutical formulations
US9662399B2 (en) 2013-02-05 2017-05-30 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10792364B2 (en) 2013-02-05 2020-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US11576974B2 (en) 2013-02-05 2023-02-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9655971B2 (en) 2013-02-05 2017-05-23 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9545448B2 (en) 2013-02-05 2017-01-17 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US11253394B2 (en) 2013-03-15 2022-02-22 Dose Medical Corporation Controlled drug delivery ocular implants and methods of using same
US10195152B2 (en) 2013-03-15 2019-02-05 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US12427057B2 (en) 2013-03-15 2025-09-30 Glaukos Corporation Controlled drug delivery ocular implants and methods of using same
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9616030B2 (en) 2013-03-15 2017-04-11 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10420726B2 (en) 2013-03-15 2019-09-24 Inspirion Delivery Sciences, Llc Abuse deterrent compositions and methods of use
US12208034B2 (en) 2013-03-15 2025-01-28 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US10517832B2 (en) 2013-03-15 2019-12-31 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US11571390B2 (en) 2013-03-15 2023-02-07 Othemo Life Sciences, Inc. Abuse deterrent compositions and methods of use
US11903908B2 (en) 2013-06-17 2024-02-20 Adamas Pharma, Llc Methods of administering amantadine
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
US10646456B2 (en) 2013-06-17 2020-05-12 Adamas Pharma, Llc Methods of administering amantadine
US10959941B2 (en) 2014-05-29 2021-03-30 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US11992551B2 (en) 2014-05-29 2024-05-28 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
US10729685B2 (en) 2014-09-15 2020-08-04 Ohemo Life Sciences Inc. Orally administrable compositions and methods of deterring abuse by intranasal administration
US11925578B2 (en) 2015-09-02 2024-03-12 Glaukos Corporation Drug delivery implants with bi-directional delivery capacity
US11564833B2 (en) 2015-09-25 2023-01-31 Glaukos Corporation Punctal implants with controlled drug delivery features and methods of using same
US20200030242A1 (en) * 2016-02-05 2020-01-30 Entrega Inc. Oral dosage form with drying agent for delivery of active agent
US11318043B2 (en) 2016-04-20 2022-05-03 Dose Medical Corporation Bioresorbable ocular drug delivery device
US12233033B2 (en) 2017-08-24 2025-02-25 Adamas Pharma, Llc Amantadine compositions, preparations thereof, and methods of use
US11077073B2 (en) 2017-08-24 2021-08-03 Adamas Pharma, Llc Methods of using amantadine compositions
US11065213B2 (en) 2017-08-24 2021-07-20 Adamas Pharma, Llc Amantadine compositions and preparations thereof
US20220047515A1 (en) * 2018-12-14 2022-02-17 Dpl Pharma S.P.A. Solid oral pharmaceutical compositions for administration of mesalazine or derivatives thereof
US20220331257A1 (en) * 2019-03-01 2022-10-20 Avadel Legacy Pharmaceuticals, Llc Liquid pharmaceutical compositions with stable drug release profiles

Also Published As

Publication number Publication date
EP2063872A1 (en) 2009-06-03
JP2010501609A (ja) 2010-01-21
MX2009002235A (es) 2009-03-13
KR20090065520A (ko) 2009-06-22
MX2009002236A (es) 2009-03-13
CA2662122A1 (en) 2008-03-06
US20160008288A1 (en) 2016-01-14
JP5788547B2 (ja) 2015-09-30
CA2662123A1 (en) 2008-03-06
AU2007291509A1 (en) 2008-03-06
ES2547226T5 (es) 2020-06-12
US9622980B2 (en) 2017-04-18
EP2063872B2 (en) 2019-12-04
ES2547226T3 (es) 2015-10-02
CA2662123C (en) 2015-12-01
US20080063711A1 (en) 2008-03-13
AU2007291509B2 (en) 2013-05-02
KR20090065519A (ko) 2009-06-22
AU2007291506A1 (en) 2008-03-06
US9101544B2 (en) 2015-08-11
KR101575679B1 (ko) 2015-12-08
WO2008025535A1 (en) 2008-03-06
JP2014114323A (ja) 2014-06-26
WO2008025532A1 (en) 2008-03-06
EP2063871A1 (en) 2009-06-03
EP2063872B1 (en) 2015-05-06
ZA200901688B (en) 2014-02-26
JP2010501607A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
EP2063872B2 (en) Controlled release oral dosage formulations comprising a core and one or more barrier layers
US20060045865A1 (en) Controlled regional oral delivery
JP5671609B2 (ja) ヒドロモルホンおよびナロキソンを含む医薬組成物
WO2010064126A2 (en) Controlled release dosage forms
EP1988881A2 (en) Oral controlled release formulation for sedative and hypnotic agents
US9387178B2 (en) Modified release tranexamic acid formulation
CN101516353B (zh) 包含核心和一个或多个阻挡层的控释口服制剂
US20080221174A1 (en) Controlled release nisoldipine compositions
EP3796908B1 (en) Controlled release propiverine formulations
AU2013202344B2 (en) Controlled release oral dosage formulations comprising a core and one or more barrier layers

Legal Events

Date Code Title Description
AS Assignment

Owner name: JAGOTEC AG, SWITZERLAND

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:GRENIER, PASCAL;NHAMIAS, ALAIN;VERGNAULT, GUY;REEL/FRAME:020354/0068;SIGNING DATES FROM 20070913 TO 20070919

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION